Daclata 60mg Tablet contains Daclatasvir, a potent direct-acting antiviral (DAA) agent used to treat chronic Hepatitis C virus (HCV) infection. It works by inhibiting the NS5A protein, which is essential for viral RNA replication and assembly. When combined with other antiviral agents such as Sofosbuvir, Daclata provides high cure rates for most HCV genotypes.

This medicine is recommended as part of combination therapy to help eliminate the virus, restore liver health, and prevent complications such as cirrhosis and hepatocellular carcinoma.

Uses / Indications:

Treatment of chronic Hepatitis C infection (genotypes 1–6)

Used in combination with Sofosbuvir or other antivirals

Helps prevent fibrosis, cirrhosis, and liver failure

Enhances sustained virologic response (SVR) outcomes

Dosage / Administration:

Typical Dose: 1 tablet (60mg) once daily.

Usually prescribed alongside Sofosbuvir 400mg.

Treatment Duration: 12–24 weeks depending on genotype and liver status.

Take with or without food, at the same time daily.

Use strictly under medical supervision.

Benefits:

High cure rate (up to 97%) when used in combination therapy.

Reduces viral load rapidly within weeks.

Promotes liver enzyme normalization and regeneration.

Prevents progression to cirrhosis or cancer.

Well-tolerated with minimal side effects.

Possible Alternates:

Daclavir 60mg Tablet